The cost of biopharmaceutical R&D: is biotech different?
作者： Joseph A. DiMasi , Henry G. Grabowski
DOI: 10.1002/MDE.1360
关键词:
摘要: … firms have focused. This study represents a first attempt to get a sense for the magnitude of the R&D costs … on a firm’s assets (the equity cost of capital) is equal to the risk-free rate plus a …
columbia.edu 
sci-hub.se 参考文章(11)
Adrian Hedley Benjamin Gottschalk, Improving the efficiency of the later stages of the drug development process : survey results from the industry, academia, and the FDA Massachusetts Institute of Technology. ,(2004)
Marilyn E. Gosse, Joseph A. DiMasi, Toben F. Nelson, Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994. Clinical Pharmacology & Therapeutics. ,vol. 60, pp. 608- 618 ,(1996) , 10.1016/S0009-9236(96)90209-X
J DiMasi, Risks in new drug development: approval success rates for investigational drugs. Clinical Pharmacology & Therapeutics. ,vol. 69, pp. 297- 307 ,(2001) , 10.1067/MCP.2001.115446
F. M. Scherer, Time-cost tradeoffs in uncertain empirical research projects Naval Research Logistics Quarterly. ,vol. 13, pp. 71- 82 ,(1966) , 10.1002/NAV.3800130106
Joseph A. DiMasi, Success rates for new drugs entering clinical testing in the United States Clinical Pharmacology & Therapeutics. ,vol. 58, pp. 1- 14 ,(1995) , 10.1016/0009-9236(95)90066-7
Janice M Reichert, Clark J Rosensweig, Laura B Faden, Matthew C Dewitz, Monoclonal antibody successes in the clinic Nature Biotechnology. ,vol. 23, pp. 1073- 1078 ,(2005) , 10.1038/NBT0905-1073
Henry Grabowski, John Vernon, Joseph A. DiMasi, Returns on Research and Development for 1990s New Drug Introductions PharmacoEconomics. ,vol. 20, pp. 11- 29 ,(2002) , 10.2165/00019053-200220003-00002
Joseph A DiMasi, Ronald W Hansen, Henry G Grabowski, The price of innovation: new estimates of drug development costs Journal of Health Economics. ,vol. 22, pp. 151- 185 ,(2003) , 10.1016/S0167-6296(02)00126-1
Janice M. Reichert, Cherie Paquette, Clinical development of therapeutic recombinant proteins. BioTechniques. ,vol. 35, pp. 176- 185 ,(2003) , 10.2144/03351DD01
Joseph A. DiMasi, Henry G. Grabowski, John Vernon, R&D Costs and Returns by Therapeutic Category Drug Information Journal. ,vol. 38, pp. 211- 223 ,(2004) , 10.1177/009286150403800301